Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants

Pediatric Infectious Disease Journal

Volumn 33, Issue 7, 2014, Pages 734-740

  Jao, Jennifer ^a   Abrams, Elaine J ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ICAP Mailman School of Public Health and College of Physicians and Surg Columbia University ^*  (United States)

Author keywords

ARV; complications; exposure; HIV; metabolic

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; MITOCHONDRIAL DNA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ARTICLE; DEATH; DNA CONTENT; DRUG SAFETY; FETAL WELL BEING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LOW BIRTH WEIGHT; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; POSTNATAL GROWTH; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SMALL FOR DATE INFANT; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; FEMALE; FETOMATERNAL TRANSFUSION; HIV INFECTIONS; INFANT; METABOLIC DISEASES; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; UNITED STATES;

ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; METABOLIC DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; UNITED STATES;

EID: 84902543309     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000224     Document Type: Article

References (90)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
2. Stek AM. Antiretroviral treatment in pregnancy. Curr Opin HIV AIDS. 2008;3:155-160.
3. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf. 2005;4:323-335.
4. Watts DH, Covington DL, Beckerman K, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol. 2004;191:985-992.
5. Barker DJ. Rise and fall of Western diseases. Nature. 1989;338:371-372.
6. Barker DJ, Winter PD, Osmond C, et al. Weight in infancy and death from ischaemic heart disease. Lancet. 1989;2:577-580.
7. Jauniaux E, Nessmann C, Imbert MC, et al. Morphological aspects of the placenta in HIV pregnancies. Placenta. 1988;9:633-642.
8. Vermaak A, Theron GB, Schubert PT, et al. Morphologic changes in the placentas of HIV-positive women and their association with degree of immune suppression. Int J Gynaecol Obstet. 2012;119:239-243.
9. Schwartz DA, Sungkarat S, Shaffer N, et al. Placental abnormalities associated with human immunodeficiency virus type 1 infection and perinatal transmission in Bangkok, Thailand. J Infect Dis. 2000;182:1652-1657.
10. Habib NA, Daltveit AK, Bergsjø P, et al. Maternal HIV status and pregnancy outcomes in northeastern Tanzania: a registry-based study. BJOG. 2008;115:616-624.
11. Ndirangu J, Newell ML, Bland RM, et al. Maternal HIV infection associated with small-for-gestational age infants but not preterm births: evidence from rural South Africa. Hum Reprod. 2012;27:1846-1856.
12. Taha TE, Dallabetta GA, Canner JK, et al. The effect of human immunodeficiency virus infection on birthweight, and infant and child mortality in urban Malawi. Int J Epidemiol. 1995;24:1022-1029.
13. Ezeaka VC, Iroha EO, Akinsulie AO, et al. Anthropometric indices of infants born to HIV-1-infected mothers: a prospective cohort study in Lagos, Nigeria. Int J STD AIDS. 2009;20:545-548.
14. Lepage P, Dabis F, Hitimana DG, et al. Perinatal transmission of HIV-1: lack of impact of maternal HIV infection on characteristics of livebirths and on neonatal mortality in Kigali, Rwanda. AIDS. 1991;5:295-300.
15. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS. 1998;12:1805-1813.
16. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère-Enfant. Lancet. 1999;353:786-792.
17. Chotpitayasunondh T, Vanprapar N, Simonds RJ, et al. Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus-infected mothers: Bangkok. Bangkok Collaborative Perinatal HIV Transmission Study Group. Pediatrics. 2001;107:E5.
18. Briand N, Le Coeur S, Traisathit P, et al. Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission. Pediatr Infect Dis J. 2006;25:325-332.
19. The European Collaborative Study. Is zidovudine therapy in pregnant HIV- infected women associated with gestational age and birthweight? AIDS. 1999;13:119-124.
20. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:716-723.
21. Feng JY, Murakami E, Zorca SM, et al. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother. 2004;48:1300-1306.
22. World Health Organization. Antiretroviral Therapy for HIV Infections in Adults and Adolescents. Recommendations for a Public Health Approach. 2010 Revision. Geneva: WHO; 2010.
23. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. Available at: http://www. unaidsrstesa.org/resources/reports/towards-universal-access-scaling-priority- hivaids-interventions-health-sector. Accessed May 10, 2013.
24. WHO. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. Progress report 2011. Available at: http://www.who.int/hiv/pub/progress-report2011/en/. Accessed May 10, 2012.
25. Siberry GK, Williams PL, Mendez H, et al.; Pediatric HIV/AIDS Cohort Study (PHACS). Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26:1151-1159.
26. Ransom CE, Huo Y, Patel K, et al.; P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr. 2013;64:374-381.
27. Gibb DM, Kizito H, Russell EC, et al.; DART trial team. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.
28. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870.
29. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:380-387.
30. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695-1705.
31. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS. 2008;22:1815-1820.
32. Watts DH, Williams PL, Kacanek D, et al.; Pediatric HIV/AIDS Cohort Study. Combination antiretroviral use and preterm birth. J Infect Dis. 2013;207:612-621.
33. Nielsen-Saines K, Komarow L, Cu-Uvin S, et al.; ACTG 5190/PACTG 1054 Study Team. Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics. 2012;129:e1525-e1532.
34. Aaron E, Bonacquisti A, Mathew L, et al. Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy. Infect Dis Obstet Gynecol. 2012;2012:135030.
35. Ross A, Raab GM, Mok J, et al. Maternal HIV infection, drug use, and growth of uninfected children in their first 3 years. Arch Dis Child. 1995;73:490-495.
36. Newell ML, Borja MC, Peckham C; European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics. 2003;111:e52-e60.
37. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999;281:151-157.
38. Hankin C, Thorne C, Newell ML; European Collaborative Study. Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr. 2005;40:364-370.
39. Ibieta MF, Cano JM, Amador JT, et al. [Growth of uninfected infants exposed to antiretrovirals born to HIV-infected woman]. An Pediatr (Barc). 2009;71:299-309.
40. Neri D, Somarriba GA, Schaefer NN, et al. Growth and body composition of uninfected children exposed to human immunodeficiency virus: comparison with a contemporary cohort and United States National Standards. J Pediatr. 2013;163:249-54.e1.
41. Powis KM, Smeaton L, Ogwu A, et al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr. 2011;56:131-138.
42. Stone B, Dockrell D, Bowman C, et al. HIV and bone disease. Arch Biochem Biophys. 2010;503:66-77.
43. Arpadi SM, Horlick M, Thornton J, et al. Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr. 2002;29:450-454.
44. Mora S, Sala N, Bricalli D, et al. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15:1823-1829.
45. Mora S, Zamproni I, Beccio S, et al. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004;89:24-28.
46. Gallant JE, Staszewski S, Pozniak AL, et al.; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral- naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
47. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19:913-918.
48. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718.
49. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008;152:582-584.
50. Giacomet V, Mora S, Martelli L, et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:448-450.
51. Tarantal AF, Marthas ML, Shaw JP, et al. Administration of 9-[ 2-®-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:323-333.
52. Tarantal AF, Castillo A, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr. 2002;29:207-220.
53. Mora S, Giacomet V, Viganò A, et al. Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. Bone. 2012;50:255-258.
54. Viganò A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther. 2011;16:1259-1266.
55. Study of effects of tenofovir on bone health and kidneys during pregnancy and breastfeeding. Available at: http://clinicaltrials.gov/ct2/show/NCT0106 6858?term=impaact+1077&rank=1. Accessed June 5, 2013.
56. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
57. König H, Behr E, Löwer J, et al. Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma. Antimicrob Agents Chemother. 1989;33:2109-2114.
58. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990;322:1098-1105.
59. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase- gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res. 1994;74:344-348.
60. Copeland WC, Chen MS, Wang TS. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem. 1992;267:21459-21464.
61. Toji L, Cohen SS. The enzymatic termination of polydeoxynucleotides by 2',3'-dideoxyadenosine triphosphate. Proc Natl Acad Sci USA. 1969;63:871-877.
62. Eriksson S, Xu B, Clayton DA. Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase. J Biol Chem. 1995;270:18929-18934.
63. Gerschenson M, Erhart SW, Paik CY, et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3'-azido-3'-deoxythymidine. AIDS Res Hum Retroviruses. 2000;16:635-644.
64. Ewings EL, Gerschenson M, St Claire MC, et al. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Syndr. 2000;24:100-105.
65. Divi RL, Leonard SL, Kuo MM, et al. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol. 2005;5:333-346.
66. Olivero OA, Torres LR, Gorjifard S, et al. Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse-transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age. J Infect Dis. 2013;208:244-248.
67. Torres SM, Walker DM, McCash CL, et al. Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1. Environ Mol Mutagen. 2009;50:10-26.
68. André-Schmutz I, Dal-Cortivo L, Six E, et al. Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination. J Infect Dis. 2013;208:235-243.
69. Poirier MC, Divi RL, Al-Harthi L, et al.; Women and Infants Transmission Study (WITS) Group. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr. 2003;33:175-183.
70. Divi RL, Walker VE, Wade NA, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS. 2004;18:1013-1021.
71. Shiramizu B, Shikuma KM, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr. 2003;32:370-374.
72. Aldrovandi GM, Chu C, Shearer WT, et al. Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics. 2009;124:e1189-e1197.
73. Côté HC, Raboud J, Bitnun A, et al. Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants. J Infect Dis. 2008;198:851-859.
74. McComsey GA, Kang M, Ross AC, et al.; AIDS Clinical Trials Group A5084. Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials. 2008;9:126-136.
75. Kunz A, von Wurmb-Schwark N, Sewangi J, et al. Zidovudine exposure in HIV-1 infected Tanzanian women increases mitochondrial DNA levels in placenta and umbilical cords. PLoS One. 2012;7:e41637.
76. Ross AC, Leong T, Avery A, et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV Med. 2012;13:98-106.
77. Maagaard A, Holberg-Petersen M, Kollberg G, et al. Mitochondrial (mt) DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther. 2006;11:601-608.
78. Gingelmaier A, Grubert TA, Kost BP, et al. Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy. Antivir Ther. 2009;14:331-338.
79. Kirmse B, Hobbs CV, Peter I, et al. Abnormal newborn screens and acylcarnitines in HIV-exposed and ARV-exposed infants. Pediatr Infect Dis J. 2013;32:146-150.
80. Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-1115.
81. Shah I. Lactic acidosis in HIV-exposed infants with perinatal exposure to antiretroviral therapy. Ann Trop Paediatr. 2009;29:257-261.
82. Noguera A, Fortuny C, Muñoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics. 2004;114:e598-e603.
83. Ekouevi DK, Touré R, Becquet R, et al.; Agence Nationale de Recherches Sur le SIDA 1201/1202 Ditrame Plus Study Group. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother- to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics. 2006;118:e1071-e1077.
84. Crain MJ, Williams PL, Griner R, et al.; Pediatric HIVAIDS Cohort Study. Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications. Pediatr Infect Dis J. 2011;30:1069-1074.
85. Barret B, Tardieu M, Rustin P, et al.; French Perinatal Cohort Study Group. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS. 2003;17:1769-1785.
86. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000;25:261-268.
87. Lindegren ML, Rhodes P, Gordon L, et al.; Perinatal Safety Review Working Group; State and Local Health Department HIV/AIDS Surveillance Programs. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci. 2000;918:222-235.
88. Brogly SB, Foca M, Deville JG, et al. Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. J Acquir Immune Defic Syndr. 2010;53:154-157.
89. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med. 2000;343:759-766.
90. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21:929-938. Development